Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results
SAN DIEGO, March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2008.
Arena reported a net loss allocable to common stockholders in the fourth quarter of 2008 of $62.5 million, or $0.84 per share, and a net loss allocable to common stockholders in the full year ended December 31, 2008 of $239.5 million, or $3.24 per share. This compares with a net loss allocable to common stockholders in the fourth quarter of 2007 of $40.9 million, or $0.60 per share, and a net loss allocable to common stockholders in the full year ended December 31, 2007 of $145.3 million, or $2.31 per share. The increased net loss in 2008 over 2007 is due primarily to Arena's Phase 3 clinical trial program of lorcaserin hydrochloride, or lorcaserin, for the treatment of obesity. Total revenues in the fourth quarter of 2008 were $2.7 million, compared to $4.6 million in the fourth quarter of 2007. Total revenues in the full year ended December 31, 2008 were $9.8 million, compared to $19.3 million in the full year ended December 31, 2007. This revenue decrease in 2008 is due primarily to reaching the end of the research funding portion of Arena's collaborations with Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc., in the fourth quarter of 2007.
"We are excited that in only a few weeks we will be announcing top-line data from the first of two pivotal trials evaluating the safety and efficacy of lorcaserin, which has the potential to be the first in a new class of drugs selectively targeting a well validated weight loss receptor," stated Jack Lief, Arena's President and Chief Executive Officer. "Given the challenging economic environment, we will continue to focus our resources on the lorcaserin program. I am optimistic that data from this program, as well as from other programs in our broad pipeline, will continue to generate interest from prospective collaborators and help in our efforts to strengthen our balance sheet."
Research and development expenses totaled $53.3 million in the fourth quarter of 2008, compared to $40.7 million in the fourth quarter of 2007. Research and development expenses totaled $204.4 million in the full year ended December 31, 2008, compared to $149.5 million in the full year ended December 31, 2007. This increase in research and development expenses in 2008 over 2007 is primarily attributable to the Phase 3 program of lorcaserin. Research and development expenses for all of 2008 included $5.0 million in non-cash, share-based compensation expense, compared to $4.2 million in 2007. General and administrative expenses totaled $8.6 million in the fourth quarter of 2008, compared to $6.9 million in the fourth quarter of 2007. General and administrative expenses totaled $30.5 million in the full year ended December 31, 2008, compared to $26.6 million in the full year ended December 31, 2007. This increase in general and administrative expenses in 2008 over 2007 is primarily attributable to increases in personnel-related expenses, as well as costs related to managing Arena's growing and maturing patent portfolio. General and administrative expenses in 2008 included $3.5 million in non-cash, share-based compensation expense, compared to $4.6 million in 2007. Total patent costs, including patent costs related to partnered programs, were $7.3 million in the full year ended December 31, 2008, compared to $6.4 million in the full year ended December 31, 2007.
Total interest and other income in 2008 reflected a net expense due to a decrease in interest income, as well as non-cash charges related to a settlement with one of Arena's two warrant holders from its Series B Convertible Preferred Stock financing and a write-down of an investment in TaiGen Biotechnology Co., Ltd. Arena redeemed all of its outstanding shares of Series B Convertible Preferred Stock in November 2008 for $55.8 million.
Cash, cash equivalents and short-term investments totaled $110.1 million at December 31, 2008. Approximately 74.1 million shares of Arena's common stock were outstanding at December 31, 2008.
Arena's Recent and 2008 Developments
-- Announced completion of dosing in BLOOM, a pivotal trial evaluating the
efficacy and safety of lorcaserin. Results from the BLOOM trial are
expected to be announced around the end of March 2009.
-- Announced publication of the Phase 2b clinical trial results of
lorcaserin in the December 4, 2008 issue of Obesity, the official peer
reviewed journal of The Obesity Society.
-- Reported findings from a planned review by an independent
Echocardiographic Safety Monitoring Board, or ESMB, in BLOOM. The
ESMB's review of unblinded echocardiographic data performed after
patients completed 12 months of dosing in the trial confirmed that
differences, if any, in the rates of Food and Drug
Administration-defined valvulopathy in patients treated with lorcaserin
and in the control group did not meet the ESMB's predetermined
-- Received net proceeds of $14.6 million as reimbursement for improvements
made to one of Arena's facilities.
-- Announced the completion of a positive randomized, double-blind,
placebo-controlled Phase 1 clinical trial and the initiation of a Phase
2 clinical trial of a second generation oral niacin receptor agonist
intended for the treatment of atherosclerosis in partnership with Merck.
-- Announced positive results from Phase 1a and Phase 1b clinical trials of
APD791 to evaluate the compound's safety, pharmacokinetics and
pharmacodynamics. APD791 is Arena's internally discovered oral drug
candidate intended for the treatment of arterial thrombosis and other
related conditions. In both trials, APD791 inhibited serotonin-mediated
amplification of platelet aggregation in a dose-dependent manner. APD791
was also generally well tolerated and rapidly absorbed and exposures
were related to dose.
-- Announced that APD597, an Arena-discovered oral GPR119 agonist for the
treatment of type 2 diabetes, was advanced into a Phase 1 clinical trial
in partnership with Ortho-McNeil-Janssen. The advancement of APD597
followed an announcement that initial clinical study results for APD668,
a first generation GPR119 agonist discovered by Arena and investigated
for the treatment of type 2 diabetes in partnership with
Ortho-McNeil-Janssen, suggest that GPR119 agonists may improve glucose
control in patients with type 2 diabetes.
-- Announced that preliminary data from a Phase 2b clinical trial of
APD125, measuring subjective endpoints in patients with primary
insomnia, indicated that APD125 did not meet the trial's primary or
secondary endpoints. Treatment with APD125 was well tolerated, and there
were no reports of serious adverse events or emerging safety findings as
compared to placebo. Arena does not anticipate any further clinical
development of APD125.
-- Entered into strategic cooperation agreements with Siegfried Ltd that
are primarily related to the manufacturing of lorcaserin. The agreements
include a long-term supply agreement for the purchase of lorcaserin
active pharmaceutical ingredient, the purchase of certain drug product
facility assets, a manufacturing services agreement and a technical
Scheduled Earnings Call
Arena will host both a conference call and webcast to discuss the fourth quarter and full year 2008 financial results and to provide a corporate update today, Thursday, March 12, 2009, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer will host the conference call.
The conference call may be accessed by dialing 877.741.4240 for domestic callers and 719.325.4753 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Fourth Quarter 2008 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; the timing and significance of the results for lorcaserin and other programs in Arena's pipeline, including with respect to potential partnering and Arena's balance sheet; and other statements about Arena's focus, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contacts: Jack Lief Mary Claire Duch
President and CEO WeissComm Partners
David Walsey 212.301.7228
Senior Director, Corporate Communications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682
Arena Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three months ended Year ended
December 31, December 31,
2008 2007 2008 2007
Manufacturing services $1,973 $- $7,434 $-
Collaborative agreements 725 4,569 2,375 19,332
Total revenues 2,698 4,569 9,809 19,332
Cost of manufacturing services 2,153 - 8,515 -
Research and development 53,325 40,690 204,374 149,524
General and administrative 8,597 6,923 30,535 26,571
Amortization of acquired
technology 565 384 2,314 1,537
Total operating expenses 64,640 47,997 245,738 177,632
Interest and other income
(expense), net (271) 3,042 (1,644) 15,134
Net loss (62,213) (40,386) (237,573) (143,166)
Dividends on redeemable
convertible preferred stock (268) (540) (1,912) (2,114)
Net loss allocable to
common stockholders $(62,481) $(40,926) $(239,485) $(145,280)
Net loss per share allocable
to common stockholders,
basic and diluted $(0.84) $(0.60) $(3.24) $(2.31)
Shares used in calculating
net loss per
share allocable to common
stockholders, basic and
diluted 74,016 68,409 73,841 62,783
Note: The Condensed Consolidated Statements of Operations has been
derived from the audited financial statements for the year ended
December 31, 2007 and from the unaudited financial statements for the
year ended December 31, 2008.
Condensed Consolidated Balance Sheet Data
December 31, December 31,
Cash, cash equivalents and short-term
investments $110,129 $398,185
Accounts receivable 1,823 1,901
Other current assets 5,031 9,162
Land, property and equipment, net 102,740 65,940
Acquired technology and other
non-current assets 21,608 12,318
Total assets $241,331 $487,506
Liabilities and Stockholders' Equity
Accounts payable and other accrued
liabilities $46,789 $30,058
Total deferred revenues 4,049 4,049
Total lease financing obligations and
other long-term liabilities 72,861 63,100
Redeemable convertible preferred stock - 53,922
Total stockholders' equity 117,632 336,377
Total liabilities and stockholders' equity $241,331 $487,506
Note: The Condensed Consolidated Balance Sheet Data has been derived from
the audited financial statements as of December 31, 2007 and from the
unaudited financial statements as of December 31, 2008.